Celadon Pharmaceuticals PLC (CEL) — Net Asset Quality Index
Celadon Pharmaceuticals PLC (CEL) has a Net Asset Quality Index of 29.0% as of June 2024. This metric measures the proportion of total assets financed by shareholders' equity — total assets of GBX8.46 Million minus total liabilities of GBX6.01 Million yields net assets of GBX2.45 Million. A higher index indicates a stronger, lower-leverage balance sheet. See CEL cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
Celadon Pharmaceuticals PLC Net Asset Quality Index Over Time (2019–2023)
This chart shows how Celadon Pharmaceuticals PLC's Net Asset Quality Index has evolved across 5 annual periods from 2019 to 2023. As of June 2024, the index stands at 29.0%, representing net assets of GBX2.45 Million against total assets of GBX8.46 Million GBX. Explore Celadon Pharmaceuticals PLC cash conversion from operations to assess how effectively this company generates cash.
Annual Net Asset Quality Index for Celadon Pharmaceuticals PLC (2019–2023)
The table below presents the year-by-year Net Asset Quality Index for Celadon Pharmaceuticals PLC from 2019 to 2023, covering 5 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Celadon Pharmaceuticals PLC (CEL) market capitalisation.
| Year | Quality Index | Net Assets (GBX) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2023 | 34.5% | GBX3.18 Million | GBX9.22 Million | GBX6.04 Million | ▼ -18.6 pp |
| 2022 | 53.1% | GBX7.04 Million | GBX13.25 Million | GBX6.21 Million | ▼ -43.9 pp |
| 2021 | 97.0% | GBX6.41 Million | GBX6.61 Million | GBX197.23K | ▲ +94.4 pp |
| 2020 | 2.6% | GBX99.03K | GBX3.85 Million | GBX3.75 Million | ▲ +7.1 pp |
| 2019 | -4.6% | GBX-113.47K | GBX2.49 Million | GBX2.60 Million | — |